CCL22 and ovarian carcinoma: These findings are in accordance with the findings of Curiel and colleagues [7], who also demonstrated significant chemotaxis of Treg cells in response to malignant ascites in ovarian carcinoma, and inhibition of chemotaxis in vitro by anti-CCL22, but not anti-CCL17.